Loading...

Horwitz, Marcus

Title(s)Professor, Medicine
SchoolMed - Infectious Diseases
Phone60074, 59324
vCardDownload vCard
    Other Positions
    Title(s)Professor, MIMG


    Collapse Research 
    Collapse Research Activities and Funding
    Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
    NIH/NIAID R01AI141390Jun 1, 2019 - May 31, 2024
    Role: Principal Investigator
    Composition, structure, and mutational analysis of the Francisella Type VI Secretion System
    NIH/NIAID R56AI125497Apr 10, 2018 - Mar 31, 2019
    Role: Principal Investigator
    Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
    NIH/NIAID R01AI135631Dec 1, 2017 - Nov 30, 2022
    Role: Principal Investigator
    Identification by High Throughput Screening of Inhibitors of Assembly and Secretion of the Francisella Type VI Secretion System
    NIH/NIAID R21AI123630Feb 1, 2016 - Jan 31, 2018
    Role: Principal Investigator
    Pre-Exposure Prophylaxis Against Francisella tularensis
    NIH/NIAID R01AI101189Jun 1, 2013 - May 31, 2017
    Role: Principal Investigator
    Pre-Exposure Prophylaxis Against Francisella tularensis
    NIH/NIAID R56AI101189Aug 1, 2012 - May 31, 2013
    Role: Principal Investigator
    Development of a tularemia vaccine that is safer and more potent than LVS
    NIH/NIAID R56AI084908Jul 6, 2010 - Jun 30, 2012
    Role: Principal Investigator
    A TB Vaccine for AIDS Patients
    NIH/NIAID R01AI068413Jan 15, 2006 - Dec 31, 2011
    Role: Principal Investigator
    Novel Antimicrobial Agents Against M. tuberculosis
    NIH/NIAID R01AI055352Jul 15, 2004 - Oct 31, 2009
    Role: Principal Investigator
    Characterization of the Francisella tularensis phagosome
    NIH/NIAID R21AI053403Sep 15, 2002 - Aug 31, 2005
    Role: Principal Investigator
    M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT &INHIBITION
    NIH/NIAID R01AI042925Apr 1, 1998 - Mar 31, 2004
    Role: Principal Investigator
    Characterization of the M. tuberculosis phagosome
    NIH/NHLBI R01HL077000Sep 30, 1993 - Aug 31, 2009
    Role: Principal Investigator
    M TUBERCULOSIS PHAGOSOME
    NIH/NIAID R01AI035275Sep 30, 1993 - Jun 30, 2004
    Role: Principal Investigator
    PROTECTIVE IMMUNITY AGAINST TUBERCULOSIS
    NIH/NIAID R01AI035189Sep 30, 1993 - Jun 30, 1999
    Role: Principal Investigator
    EXOCHELINS, TUBERCULOSIS, AND AIDS
    NIH/NIAID R01AI033790Jan 1, 1993 - Dec 31, 1996
    Role: Principal Investigator
    Development and Testing of New Tuberculosis Vaccines
    NIH/NIAID R01AI031338Apr 1, 1991 - May 31, 2005
    Role: Principal Investigator
    IRON AND MONOCYTE ACTIVATION AGAINST A LUNG PATHOGEN
    NIH/NIAID R01AI028825Feb 1, 1990 - Jan 31, 1996
    Role: Principal Investigator
    BIOLOGY OF MYCOBACTERIUM LEPRAE MONOCYTE INTERACTION
    NIH/NIAID R01AI025143Jul 1, 1988 - Jun 30, 1992
    Role: Principal Investigator
    BIOLOGY OF MYCOBACTERIUM LEPRAE MONOCYTE INTERACTION
    NIH/NIAID R22AI025143Jul 1, 1988 - Jun 30, 1991
    Role: Principal Investigator
    COMPLEMENT AND OPPORTUNISTIC MYCOBACTERIA IN AIDS
    NIH/NIAID R01AI025681Sep 30, 1987 - Nov 30, 1991
    Role: Principal Investigator
    IMMUNE RESPONSE TO AN INTRACELLULAR PULMONARY PATHOGEN
    NIH/NIAID R01AI022421Sep 1, 1985 - Jun 30, 1995
    Role: Principal Investigator
    TRANSMISSION ELECTRON MICROSCOPE AND MICROTOME
    NIH/NCRR S10RR002334Jan 1, 1985 - Dec 31, 1985
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Yang X, Clemens DL, Lee BY, Cui Y, Zhou ZH, Horwitz MA. Atomic Structure of the Francisella T6SS Central Spike Reveals a Unique a-Helical Lid and a Putative Cargo. Structure. 2019 12 03; 27(12):1811-1819.e6. PMID: 31677891.
      View in: PubMed
    2. Clemens DL, Lee BY, Silva A, Dillon BJ, Masleša-Galic S, Nava S, Ding X, Ho CM, Horwitz MA. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLoS One. 2019; 14(5):e0215607. PMID: 31075149.
      View in: PubMed
    3. Tullius MV, Nava S, Horwitz MA. PPE37 Is Essential for Mycobacterium tuberculosis Heme-Iron Acquisition (HIA), and a Defective PPE37 in Mycobacterium bovis BCG Prevents HIA. Infect Immun. 2019 02; 87(2). PMID: 30455201.
      View in: PubMed
    4. Clemens DL, Lee BY, Plamthottam S, Tullius MV, Wang R, Yu CJ, Li Z, Dillon BJ, Zink JI, Horwitz MA. Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model. ACS Infect Dis. 2019 02 08; 5(2):281-291. PMID: 30480992.
      View in: PubMed
    5. Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galic S, Nava S, Ho CM, Horwitz MA. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. PLoS One. 2018; 13(11):e0207469. PMID: 30427938.
      View in: PubMed
    6. Jia Q, Horwitz MA. Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis. Front Cell Infect Microbiol. 2018; 8:154. PMID: 29868510.
      View in: PubMed
    7. Jia Q, Bowen R, Dillon BJ, Masleša-Galic S, Chang BT, Kaidi AC, Horwitz MA. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep. 2018 05 03; 8(1):7009. PMID: 29725025.
      View in: PubMed
    8. Clemens DL, Lee BY, Horwitz MA. The Francisella Type VI Secretion System. Front Cell Infect Microbiol. 2018; 8:121. PMID: 29740542.
      View in: PubMed
    9. Jia Q, Dillon BJ, Masleša-Galic S, Horwitz MA. Listeria-Vectored Vaccine Expressing the Mycobacterium tuberculosis 30-Kilodalton Major Secretory Protein via the Constitutively Active prfA* Regulon Boosts Mycobacterium bovis BCG Efficacy against Tuberculosis. Infect Immun. 2017 Sep; 85(9). PMID: 28630063.
      View in: PubMed
    10. Ruehle B, Clemens DL, Lee BY, Horwitz MA, Zink JI. A Pathogen-Specific Cargo Delivery Platform Based on Mesoporous Silica Nanoparticles. J Am Chem Soc. 2017 05 17; 139(19):6663-6668. PMID: 28437093.
      View in: PubMed
    11. Stefanova D, Raychev A, Arezes J, Ruchala P, Gabayan V, Skurnik M, Dillon BJ, Horwitz MA, Ganz T, Bulut Y, Nemeth E. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood. 2017 07 20; 130(3):245-257. PMID: 28465342.
      View in: PubMed
    12. Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galic S, Nava S, Ding X, Ho CM, Horwitz MA. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time. Nat Commun. 2017 01 24; 8:14183. PMID: 28117835.
      View in: PubMed
    13. Jia Q, Bowen R, Lee BY, Dillon BJ, Masleša-Galic S, Horwitz MA. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge. Vaccine. 2016 09 22; 34(41):4969-4978. PMID: 27577555.
      View in: PubMed
    14. Lee BY, Li Z, Clemens DL, Dillon BJ, Hwang AA, Zink JI, Horwitz MA. Redox-Triggered Release of Moxifloxacin from Mesoporous Silica Nanoparticles Functionalized with Disulfide Snap-Tops Enhances Efficacy Against Pneumonic Tularemia in Mice. Small. 2016 Jul; 12(27):3690-702. PMID: 27246117.
      View in: PubMed
    15. Silva A, Lee BY, Clemens DL, Kee T, Ding X, Ho CM, Horwitz MA. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc Natl Acad Sci U S A. 2016 Apr 12; 113(15):E2172-9. PMID: 27035987.
      View in: PubMed
    16. Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, Herskovitz J, Elsaesser H, Snell LM, Wilson EB, de la Torre JC, Kitchen SG, Horwitz MA, Bensinger SJ, Smale ST, Brooks DG. Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence. PLoS Pathog. 2016 Jan; 12(1):e1005356. PMID: 26808628.
      View in: PubMed
    17. Li Z, Clemens DL, Lee BY, Dillon BJ, Horwitz MA, Zink JI. Mesoporous Silica Nanoparticles with pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic Tularemia. ACS Nano. 2015 Nov 24; 9(11):10778-89. PMID: 26435204.
      View in: PubMed
    18. Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA. Tuberculosis: pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice (Small 38/2015). Small. 2015 Oct; 11(38):5065. PMID: 26450161.
      View in: PubMed
    19. Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA. pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice. Small. 2015 Oct; 11(38):5066-78. PMID: 26193431.
      View in: PubMed
    20. Clemens DL, Ge P, Lee BY, Horwitz MA, Zhou ZH. Atomic structure of T6SS reveals interlaced array essential to function. Cell. 2015 Feb 26; 160(5):940-951. PMID: 25723168.
      View in: PubMed
    21. Gillis TP, Tullius MV, Horwitz MA. rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B. Infect Immun. 2014 Sep; 82(9):3900-9. PMID: 25001602.
      View in: PubMed
    22. Lacan G, Dang H, Middleton B, Horwitz MA, Tian J, Melega WP, Kaufman DL. Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci Res. 2013 Oct; 91(10):1292-302. PMID: 23907992.
      View in: PubMed
    23. Jia Q, Bowen R, Sahakian J, Dillon BJ, Horwitz MA. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge. Infect Immun. 2013 May; 81(5):1550-61. PMID: 23439306.
      View in: PubMed
    24. Clemens DL, Lee BY, Xue M, Thomas CR, Meng H, Ferris D, Nel AE, Zink JI, Horwitz MA. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob Agents Chemother. 2012 May; 56(5):2535-45. PMID: 22354311.
      View in: PubMed
    25. Clemens DL, Lee BY, Horwitz MA. O-antigen-deficient Francisella tularensis Live Vaccine Strain mutants are ingested via an aberrant form of looping phagocytosis and show altered kinetics of intracellular trafficking in human macrophages. Infect Immun. 2012 Mar; 80(3):952-67. PMID: 22202123.
      View in: PubMed
    26. Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect Immun. 2010 Oct; 78(10):4341-55. PMID: 20643859.
      View in: PubMed
    27. Lee BY, Jethwaney D, Schilling B, Clemens DL, Gibson BW, Horwitz MA. The Mycobacterium bovis bacille Calmette-Guerin phagosome proteome. Mol Cell Proteomics. 2010 Jan; 9(1):32-53. PMID: 19815536.
      View in: PubMed
    28. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga C, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, Sadoff JC. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine. 2009 Jul 16; 27(33):4412-23. PMID: 19500523.
      View in: PubMed
    29. Clemens DL, Lee BY, Horwitz MA. Francisella tularensis phagosomal escape does not require acidification of the phagosome. Infect Immun. 2009 May; 77(5):1757-73. PMID: 19237528.
      View in: PubMed
    30. Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine. 2009 Feb 18; 27(8):1216-29. PMID: 19126421.
      View in: PubMed
    31. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, Sadoff JC, Horwitz MA. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis. 2008 Nov 15; 198(10):1491-501. PMID: 18808333.
      View in: PubMed
    32. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine. 2009 Jan 14; 27(3):441-5. PMID: 19007841.
      View in: PubMed
    33. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun. 2008 Nov; 76(11):5200-14. PMID: 18725418.
      View in: PubMed
    34. Lee BY, Clemens DL, Horwitz MA. The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages. Mol Microbiol. 2008 May; 68(4):1047-60. PMID: 18363792.
      View in: PubMed
    35. Harth G, Zamecnik PC, Tabatadze D, Pierson K, Horwitz MA. Hairpin extensions enhance the efficacy of mycolyl transferase-specific antisense oligonucleotides targeting Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2007 Apr 24; 104(17):7199-204. PMID: 17438292.
      View in: PubMed
    36. Lee BY, Horwitz MA, Clemens DL. Identification, recombinant expression, immunolocalization in macrophages, and T-cell responsiveness of the major extracellular proteins of Francisella tularensis. Infect Immun. 2006 Jul; 74(7):4002-13. PMID: 16790773.
      View in: PubMed
    37. Harth G, Maslesa-Galic S, Tullius MV, Horwitz MA. All four Mycobacterium tuberculosis glnA genes encode glutamine synthetase activities but only GlnA1 is abundantly expressed and essential for bacterial homeostasis. Mol Microbiol. 2005 Nov; 58(4):1157-72. PMID: 16262797.
      View in: PubMed
    38. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine. 2006 Mar 06; 24(10):1593-600. PMID: 16257099.
      View in: PubMed
    39. Clemens DL, Lee BY, Horwitz MA. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect Immun. 2005 Sep; 73(9):5892-902. PMID: 16113308.
      View in: PubMed
    40. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. Vaccine. 2006 Jan 23; 24(4):443-51. PMID: 16125825.
      View in: PubMed
    41. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun. 2005 Aug; 73(8):4676-83. PMID: 16040980.
      View in: PubMed
    42. Horwitz MA. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect. 2005 May; 7(5-6):947-54. PMID: 15919223.
      View in: PubMed
    43. Harth G, Masleša-Galic S, Horwitz MA. A two-plasmid system for stable, selective-pressure-independent expression of multiple extracellular proteins in mycobacteria. Microbiology. 2004 Jul; 150(Pt 7):2143-2151. PMID: 15256557.
      View in: PubMed
    44. Clemens DL, Lee BY, Horwitz MA. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect Immun. 2004 Jun; 72(6):3204-17. PMID: 15155622.
      View in: PubMed
    45. Tullius MV, Harth G, Horwitz MA. Glutamine synthetase GlnA1 is essential for growth of Mycobacterium tuberculosis in human THP-1 macrophages and guinea pigs. Infect Immun. 2003 Jul; 71(7):3927-36. PMID: 12819079.
      View in: PubMed
    46. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun. 2003 Apr; 71(4):1672-9. PMID: 12654780.
      View in: PubMed
    47. Harth G, Horwitz MA. Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo. Infect Immun. 2003 Jan; 71(1):456-64. PMID: 12496196.
      View in: PubMed
    48. Harth G, Horwitz MA, Tabatadze D, Zamecnik PC. Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology. Proc Natl Acad Sci U S A. 2002 Nov 26; 99(24):15614-9. PMID: 12427974.
      View in: PubMed
    49. Clemens DL, Lee BY, Horwitz MA. The Mycobacterium tuberculosis phagosome in human macrophages is isolated from the host cell cytoplasm. Infect Immun. 2002 Oct; 70(10):5800-7. PMID: 12228310.
      View in: PubMed
    50. Amersi F, Nelson SK, Shen XD, Kato H, Melinek J, Kupiec-Weglinski JW, Horwitz LD, Busuttil RW, Horwitz MA. Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Proc Natl Acad Sci U S A. 2002 Jun 25; 99(13):8915-20. PMID: 12084933.
      View in: PubMed
    51. Whitekus MJ, Li N, Zhang M, Wang M, Horwitz MA, Nelson SK, Horwitz LD, Brechun N, Diaz-Sanchez D, Nel AE. Thiol antioxidants inhibit the adjuvant effects of aerosolized diesel exhaust particles in a murine model for ovalbumin sensitization. J Immunol. 2002 Mar 01; 168(5):2560-7. PMID: 11859152.
      View in: PubMed